/MVRBF

MVRBF Stock - Medivir AB (publ)

Q: What is the analyst price target for MVRBF?

Analyst price target information is not currently available for MVRBF.

Q: What is MVRBF's market cap?

Market capitalization information is not currently available for MVRBF.

Healthcare|Biotechnology|OTC

$0.82+0.00%

+$0.00 (+0.00%) • Feb 1

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.90

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MVRBF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.36

52W High$0.90

52W Low$0.68

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$4.41M	$25.54M	$13.95M	$8.72M	$23.86M
Gross Profit	$4.41M	$25.54M	$13.95M	$8.72M	$23.86M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-87,354,000	$-62,118,000	$-42,900,000	$-125,979,000	$-351,030,000
Net Income	$-88,765,000	$-63,125,000	$-42,620,000	$-123,440,000	$-350,314,000
Net Margin	-2013.7%	-247.2%	-305.6%	-1414.9%	-1468.0%
EPS	$-1.59	$-1.20	$-1.44	$-4.17	$-12.01

Company Overview

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Visit Website

Earnings History & Surprises

MVRBF

Beat Rate

67%

Last 15 quarters

Avg Surprise

+20.3%

EPS vs Estimate

Beats / Misses

10/5

Last 12 quarters

Latest EPS

$-0.32

Q1 2023

EPS Surprise History

Q2 21

+67.3%

$-0.18vs$-0.55

Q3 21

+22.2%

$-0.35vs$-0.45

Q4 21

-44.4%

$-0.26vs$-0.18

Q1 22

-33.3%

$-0.44vs$-0.33

Q2 22

-59.5%

$-0.59vs$-0.37

Q3 22

+16.0%

$-0.42vs$-0.50

Q4 22

+44.9%

$-0.27vs$-0.49

Q1 23

-14.3%

$-0.32vs$-0.28

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2023	Feb 15, 2023	$-0.28	$-0.32	-14.3%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.49	$-0.27	+44.9%	✓ BEAT
Q3 2022	Aug 19, 2022	$-0.50	$-0.42	+16.0%	✓ BEAT
Q2 2022	Apr 28, 2022	$-0.37	$-0.59	-59.5%	✗ MISS
Q1 2022	Feb 15, 2022	$-0.33	$-0.44	-33.3%	✗ MISS
Q4 2021	Nov 3, 2021	$-0.18	$-0.26	-44.4%	✗ MISS
Q3 2021	Aug 19, 2021	$-0.45	$-0.35	+22.2%	✓ BEAT
Q2 2021	Apr 28, 2021	$-0.55	$-0.18	+67.3%	✓ BEAT
Q1 2021	Feb 26, 2021	$-1.03	$-0.46	+55.3%	✓ BEAT
Q4 2020	Nov 10, 2020	$-0.59	$0.16	+127.1%	✓ BEAT
Q3 2020	Aug 20, 2020	$-0.93	$-0.43	+53.8%	✓ BEAT
Q2 2020	May 5, 2020	$-1.02	$-0.79	+22.5%	✓ BEAT
Q1 2020	Feb 13, 2020	$-0.75	$-1.08	-44.0%	✗ MISS
Q4 2019	Nov 27, 2019	$-0.88	$-0.78	+11.4%	✓ BEAT
Q3 2019	Aug 28, 2019	$-2.01	$-0.42	+79.1%	✓ BEAT
Q2 2019	May 3, 2019	—	$-0.20	—	—
Q1 2019	Feb 14, 2019	—	$-0.36	—	—
Q4 2018	Oct 26, 2018	—	$-0.27	—	—
Q3 2018	Jul 25, 2018	—	$-0.35	—	—
Q2 2018	Apr 27, 2018	—	$-0.31	—	—